Important Information About BLENREP (belantamab mafodotin-blmf)

On November 22, 2022, GSK announced the initiation of the withdrawal of the US marketing authorization for BLENREP.

The US Food and Drug Administration (FDA) withdrew the US license to manufacture BLENREP on February 6, 2023. Along with the withdrawal of the license, the BLENREP REMS (Risk Evaluation and Mitigation Strategy) is no longer in effect.

If you have questions, please contact the GSK Response Center.

Visit our website, or call 1-877-768-0092.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Trademarks are owned by or licensed to the GSK group of companies.